Cover Image
市場調查報告書

Cortex Pharmaceuticals, Inc.:產品平台分析

Cortex Pharmaceuticals, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 224645
出版日期 內容資訊 英文 41 Pages
訂單完成後即時交付
價格
Back to Top
Cortex Pharmaceuticals, Inc.:產品平台分析 Cortex Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日期: 2015年08月31日 內容資訊: 英文 41 Pages
簡介

Cortex Pharmaceuticals, Inc.正在致力於開發及商品化治療睡眠呼吸中止症和藥物性呼吸障礙等嚴重關乎生死的慢性病之新產品。該公司總公司設置於美國紐澤西州,同時也在英國發展事業。

本報告提供Cortex Pharmaceuticals, Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃相關等資訊。

Cortex Pharmaceuticals, Inc.的基本資料

Cortex Pharmaceuticals, Inc.概要

  • 主要資訊
  • 企業資料

Cortex Pharmaceuticals, Inc.:R&D概要

  • 主要的治療範圍

Cortex Pharmaceuticals, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Cortex Pharmaceuticals, Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第Ⅱ階段的產品/聯合治療模式
    • 第Ⅰ階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Cortex Pharmaceuticals, Inc.:藥物簡介

  • CX-1739
  • dronabinol
  • CX-717
  • CX-1846
  • CX-1942
  • CX-2007
  • CX-2076
  • CX-929

Cortex Pharmaceuticals, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Cortex Pharmaceuticals, Inc.:最近的開發平台趨勢

Cortex Pharmaceuticals, Inc.:暫停中的計劃

Cortex Pharmaceuticals, Inc.:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • CX-516

Cortex Pharmaceuticals, Inc.:企業發表

Cortex Pharmaceuticals, Inc.:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07373CDB

Summary

Global Markets Direct's, 'Cortex Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Cortex Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Cortex Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Cortex Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Cortex Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Cortex Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Cortex Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Cortex Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Cortex Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Cortex Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cortex Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Cortex Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Cortex Pharmaceuticals, Inc. Snapshot
    • Cortex Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Cortex Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Cortex Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Cortex Pharmaceuticals, Inc. - Pipeline Products Glance
    • Cortex Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Cortex Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Cortex Pharmaceuticals, Inc. - Drug Profiles
    • CX-1739
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dronabinol
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CX-717
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CX-1846
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CX-1942
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CX-2007
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CX-2076
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CX-929
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Cortex Pharmaceuticals, Inc. - Pipeline Analysis
    • Cortex Pharmaceuticals, Inc. - Pipeline Products by Target
    • Cortex Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Cortex Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Cortex Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Cortex Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Cortex Pharmaceuticals, Inc. - Dormant Projects
  • Cortex Pharmaceuticals, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • CX-516
  • Cortex Pharmaceuticals, Inc. - Company Statement
  • Cortex Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Cortex Pharmaceuticals, Inc., Key Information
  • Cortex Pharmaceuticals, Inc., Key Facts
  • Cortex Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • Cortex Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Cortex Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Cortex Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2015
  • Cortex Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Cortex Pharmaceuticals, Inc. - Phase II, 2015
  • Cortex Pharmaceuticals, Inc. - Phase I, 2015
  • Cortex Pharmaceuticals, Inc. - Preclinical, 2015
  • Cortex Pharmaceuticals, Inc. - Pipeline by Target, 2015
  • Cortex Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
  • Cortex Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • Cortex Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Cortex Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015
  • Cortex Pharmaceuticals, Inc. - Dormant Developmental Projects,2015
  • Cortex Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2015
  • Cortex Pharmaceuticals, Inc., Subsidiaries

List of Figures

  • Cortex Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
  • Cortex Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Cortex Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Cortex Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • Cortex Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Cortex Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Cortex Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top